Typical timeline
6–24 months
Class D IVDs (highest risk, e.g. blood-screening tests) face the most Notified Body scrutiny and the longest timelines.
European Union
The EU regulation governing in vitro diagnostic devices — the IVD counterpart to the MDR.
Overview
Regulation (EU) 2017/746 governs in vitro diagnostic medical devices in the EU/EEA. It introduced a risk-based classification system (Class A–D) and dramatically expanded the share of IVDs requiring Notified Body involvement compared to the prior IVD Directive.
Requirements
The documentation and evidence a complete submission is normally built from.
Planning ranges
Ranges illustrate general market patterns for this pathway — they are not a quote for a specific product.
Typical timeline
6–24 months
Class D IVDs (highest risk, e.g. blood-screening tests) face the most Notified Body scrutiny and the longest timelines.
Estimated cost
$20k–$200k
Higher-risk classes with clinical performance studies carry substantially higher cost than the equivalent device class under the old IVDD.
Timelines and costs above are typical ranges illustrating general market patterns, not a quote or regulatory conclusion for your specific product. Actual figures depend on device classification, target country, and applicant readiness — professional review is required before relying on this for a business decision.
Where this applies
Jurisdictions that recognise this certification. Scope and conditions still vary by product classification.
Related
FAQ
IVDR moved roughly 80% of IVDs into categories requiring Notified Body review, versus roughly 20% under the previous IVDD — many previously self-certified products are newly in scope.
Related
The conformity mark required to sell medical devices in the EU/EEA, issued once a device meets EU MDR or IVDR requirements.
View →
The EU regulation that defines medical device requirements — CE Marking is the certification mark it produces once satisfied.
View →
The international quality management system standard specific to medical device manufacturers, referenced by most major regulators.
View →
Reviewed packages
Buy a defined outcome
Market Entry Sprint from $2,500 · Strategy Session $500 · Pathway Brief $1,800. Professional review required before business use. No patient data on public forms.
Reviewed launch planning
IVDR pathway briefs start at $1,800. Or book a $2,500 Market Entry Sprint that includes regulatory pathway outline, evidence flags, and a review call.
Professional review is required before business use.